Accelerator Life Sciences launches Magnolia Neurosciences with $31 mln Series A

Accelerator Life Science Partners has launched Magnolia Neurosciences Corp with $31 million in Series A funding. The investors included AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Innovate NY Fund, Johnson & Johnson Innovation – JJDC, Inc., the Partnership Fund for New York City, Pfizer Ventures, Watson Fund, L.P., WuXi AppTec’s Corporate Venture Fund and 180 Degree Capital Corp. Magnolia Neurosciences is a developer of neuroprotective therapies.

Source: Press Release